| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PIK-93, a phenylthiazole analog, is a novel, potent, and selective PI4K (PI4KIIIβ) inhibitor with antiviral effects (antienterovirus activity). It inhibits PI4K (PI4KIIIβ) with an IC50 of 19 nM and PI3Kα with an IC50 of 39 NM.
| Targets |
PI4KIIIβ (IC50 = 19 nM); PI4KIIIα (IC50 = 1.1 μM); p110γ (IC50 = 16 nM); p110α (IC50 = 39 nM); p110δ (IC50 = 120 nM); p110β (IC50 = 590 nM); PI3KC2β (IC50 = 140 nM); PI3KC2α (IC50 = 16 μM); hsVPS34 (IC50 = 320 nM); DNA-PK (IC50 = 64 nM); ATM (IC50 = 490 nM); mTORC1 (IC50 = 1.38 μM); ATR (IC50 = 17 μM)
|
|---|---|
| ln Vitro |
PIK-93 inhibits PI3Kγ and PI4KIIIβ, with IC50 values of 16 nM and 19 nM, respectively. PIK-93 also inhibits other members of PI3Ks, including PI3Kα, β, and δ, with IC50 values of 39 nM, 0.59 μM, and 0.12 μM, respectively. Even at a concentration of 10 M, PIK-93 has no discernible inhibitory effect on a panel of other kinases[1]. PIK-93 (0.5 M-1 M) decreases the consolidation and stability of the leading edge formed after treatment with uniform f-Met-Leu-Phe (fMLP) in differentiated HL60 (dHL60) cells. The fMLP-dependent accumulation of total F-actin is altered by PIK-93, but not in terms of quantity. PIK-93 increases cell turning frequency while decreasing the chemotactic index in fMLP gradients[2]. In COS-7 cells, PIK-93 (250 nM) successfully prevents the buildup of FL-Cer and the CERT-PH domain in the Golgi. The same concentration of PIK-93 also significantly reduces the ability of endogenous ceramide to transform into sphingomyelin when labeled with [3H]serine. These facts suggest that PI4KIIIβ plays a critical role in the regulation of spingomyelin synthesis as well as ceramide transport between the ER and Golgi[3]. PIK-93 (300 nM) inhibits net Ca2+ entry and carbachol-induced translocation of TRPC6 to the plasma membrane in T6.11 cells[4]. According to a recent study, PIK-93 has anti-enterovirus properties because it inhibits the replication of the poliovirus (PV) and the hepatitis C virus (HCV), with EC50 values of 0.14 µM and 1.9 µM, respectively[5].
|
| ln Vivo |
N/A
|
| Enzyme Assay |
Standard TLC lipid kinase activity assays are used to calculate IC50 values. In order to carry out kinase reactions, a reaction mixture containing kinase, PIK-93 (2% DMSO final concentration), buffer (25 mM HEPES, pH 7.4, 10 mM MgCl2), and freshly sonicated phosphatidylinositol (100 µg/mL) must be prepared. A final concentration of 10 or 100 µM is used to start the reactions, and they are then allowed to continue for 20 min at room temperature. The starting material for the reactions is ATP containing 10 µCi of γ-32P-ATP. The addition of 105 µL 1N HCl and 160 l of CHCl3:MeOH (1:1) then ends the reactions in preparation for TLC analysis. The organic phase is transferred to a new tube using a gel loading pipette tip that has been CHCl3-precoated after the biphasic mixture has been vortexed and briefly centrifuged. In a 65:35 solution of n-propanol:1M acetic acid, this extract is spotted on TLC plates and developed for 3–4 hours. Following drying, the TLC plates are shown to a phosphorimager screen and quantitated. As a two-fold dilution from the highest concentration of 100 μM, kinase activity is typically assessed at 10–12 concentrations of PIK–93.
|
| Cell Assay |
For actin staining, dHL60 cells are preincubated in suspension with PIK-93 or vehicle for 40 min, centrifuged for 5 min at 2000 rpm at room temperature in a J6-B centrifuge, resuspended in mHBSS containing the appropriate agent at the same concentration, and then allowed to adhere to fibronectin-covered coverslips for 3 min. Rhodamine-phalloidin (10 units/mL) is used to stain cells that have been fixed in 3.7% PFA for 15 minutes.
|
| Animal Protocol |
N/A;
|
| References |
|
| Molecular Formula |
C14H16N3O4S2CL
|
|---|---|
| Molecular Weight |
389.87754
|
| Exact Mass |
389.027
|
| Elemental Analysis |
C, 43.13; H, 4.14; Cl, 9.09; N, 10.78; O, 16.41; S, 16.45
|
| CAS # |
593960-11-3
|
| Related CAS # |
593960-11-3;
|
| PubChem CID |
6852167
|
| Appearance |
White to off-white solid powder
|
| Density |
1.48 g/cm3
|
| Boiling Point |
611.8ºC at 760 mmHg
|
| Flash Point |
323.8ºC
|
| LogP |
4.122
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
543
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(NC1=NC(C)=C(S1)C2=CC=C(C(S(=O)(NCCO)=O)=C2)Cl)=O
|
| InChi Key |
JFVNFXCESCXMBC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)
|
| Chemical Name |
N-(5-(4-chloro-3-(N-(2-hydroxyethyl)sulfamoyl)phenyl)-4-methylthiazol-2-yl)acetamide
|
| Synonyms |
PIK-93; PIK93; PIK 93
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~78 mg/mL (200.1 mM)
Water: <1 mg/mL Ethanol: <1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (11.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% PEG400+0.5% Tween80+5%Propylene glycol:30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5649 mL | 12.8245 mL | 25.6489 mL | |
| 5 mM | 0.5130 mL | 2.5649 mL | 5.1298 mL | |
| 10 mM | 0.2565 mL | 1.2824 mL | 2.5649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA